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demonstrates that the T-SPeC® device can be placed safely 
and efficiently in a variety of patients with a need for uri-
nary drainage.
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Instrumentation · Incontinence
Introduction
The Transurethral Suprapubic endo-Cystostomy Device 
(T-SPeC®) is a novel disposable medical device used for 
insertion of a suprapubic catheter (SPC) via a transurethral 
approach (Fig. 1). The T-SPeC® device (Swan Valley Medi-
cal Inc. Bigfork, MT) has FDA 510(k) clearances. T-SPeC® 
device compensates for abdominal girth to allow accurate and 
efficient catheter placement from an ‘inside-out’ direction. 
T-SPeC® Surgical System comes in two models, T7 and T14. 
The T7 model can accommodate a bladder to skin distance of 
up to 7 cm, while the T14 can accommodate 14 cm. T-SPeC® 
is similar to the Lowsley retractor that was used commonly 
for suprapubic cystostomy catheterization before the devel-
opment of percutaneous SPC kits [1]. However, unlike 
the Lowsley device that requires an incision to cut down to 
expose the tip of the curved metal sound, the T-SPeC® instru-
ment initiates a 15 Fr surgical tract from within the bladder 
and exits the skin just cephalad to the pubic bone.
In 2013, the senior author (BJF) and colleagues pub-
lished a pilot study that demonstrated the proof of concept 
on a cadaver model as well as initial experience in four men 
at St. Mary’s General Hospital in Kitchener Ontario, Can-
ada [2]. These live cases were performed in the outpatient 
setting successfully using the T-SPeC® T7 Surgical Sys-
tem in a mean of 9.7 min under general anesthesia without 
any complications. Once feasibility was demonstrated and 
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FDA clearance occurred, one of the authors (BJF) elected 
to study this device in his practice. We prospectively evalu-
ated the new medical device T-SPeC® and examined the 
30-day outcomes in the first US series.
Materials and methods
Patients
This was an IRB-approved prospective case series 
(COMIRB #14-0378) of 114 consecutive patients who 
underwent suprapubic catheter placement with the T-SPeC® 
device as part of complex genitourinary reconstruction or 
an isolated procedure. After informed consent, the patient 
underwent suprapubic catheter placement via the T-SPeC® 
device by a single surgeon at the University of Colorado 
Hospital in Aurora, CO, between November 2012 and July 
2014. Data were collected prospectively from the time of 
the preoperative visit until the 30-day postoperative visit.
Surgical technique
The procedure commenced after an appropriate anesthetic 
and antibiotic had been administered. All patients were 
placed in a dorsal lithotomy position prior to placement of 
the sound. In the male patient, cystoscopy was performed 
next to evaluate for urethral pathology. Cystoscopy was 
not routinely performed prior to placement of the sound 
on female patients. Figure 2 overviews the key steps of the 
procedure, the skin is marked 2 cm cephalad to the pubic 
bone in the midline, mast and alignment arm are attached 
to the device, which automatically places the capture hous-
ing directly over the tip of the internal end of the sound, on 
the abdominal surface. The internal tip of the sound is pal-
pated under the site mark. The shaft of the T-SPeC® device 
is then tilted 10° below horizontal, and the safety switch is 
disabled.
The advancement handle is moved forward to the des-
ignated depth, which sends the cutting blade sequentially 
through the end of the sound, the bladder, the subcutaneous 
tissue, and into the capture housing. The blade, alignment 
arm and mast are then removed. Next, the prepackaged 18 
Fr catheter is attached to the bayonet connector. A 1-mm 
incision is made in the skin adjacent to the sound exiting 
the skin. The catheter and sound are then pulled into the 
bladder and then exit at the urethral meatus. The catheter 
is disconnected and then advanced back into the bladder 
with a cystoscope. The balloon is inflated with 10 ml of 
sterile water. Accurate catheter placement is then confirmed 
by cystoscopy. There is no need to suture the catheter to 
the skin at the end of the procedure. The distance from the 
bladder to the skin was measured both intra-operatively 
and postoperatively by the 1-cm incremental markings on 
the catheter from the balloon to the hub (Fig. 3). Opera-
tive time was recorded from the time of placing the T-SPeC 
sound in the urethra to the end of the cystoscopy.
Results
Table 1 details the patient demographics in 114 patients. 
The indication for SPC placement was chronic bladder 
drainage in 12 % and temporary postoperative urinary 
drainage in 88 %. Almost half of the patients (45.6 %) 
in the study were obese (BMI > 30 kg/m2), 12 % of 
patients had neurologic disease, 15.8 % of patients had 
a history of recurrent UTIs, and many patients had prior 
abdominal surgery (appendectomy, ileostomy/colostomy, 
colectomy, cholecystectomy, gastric bypass or gastric 
fundoplication). Despite a significant number of patients 
with neurologic disease and morbid obesity, all patients 
were placed in lithotomy position. <10 % of patients had 
preoperative imaging. Those with preoperative imag-
ing included patients undergoing major urinary tract 
reconstructive procedures such as vesicovaginal fistula, 
enterovesical fistula, posterior urethroplasty and bladder 
diverticulectomy.
Fig. 1  Schematic of the T-SPeC® Surgical System. The rear advance-
ment handle advances the cutting blade (15 Fr) from inside the blad-
der, through the bladder wall and abdomen, and pulls the catheter 
connected to the bayonet connector on the coaxial coil back through 
the surgical pathway for placement in the bladder. The locking mech-
anism in the rear handle prevents the cutting blade and coaxial coil 
from being inadvertently advanced. The mast guides the alignment 
arm to the patient’s abdomen before creation of the surgical pathway. 
Abdominal thickness can be measured using the graduated mast. The 
alignment arm holding the capture housing provides the surgeon with 
the blade exit point. The cutting blade makes a small incision (15 Fr) 
through the bladder, fascia and abdominal wall. It is housed within 
the sound and is deployed by the rear advancement handle. The cap-
ture housing accepts the surgical blade once it has passed through the 
patient’s bladder wall and abdomen. The blade and capture housing 
can be removed for disposal by rotating the capture housing
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Outcome measures of the T-SPeC® procedure are as fol-
lows. The majority of the T-SPeC® procedures used the T7 
device (67.5 %) and were performed under general anes-
thesia (93 %) as most of cases were done in combination 
with major pelvic surgery. The mean operative time was 
3.6 min (range 2.5–5.5 min), and the average abdominal 
wall thickness was 6.7 cm (4–11 cm). There were only 
two procedural difficulties (1.8 %). In these two cases, the 
capture housing was missed. The knife blade was removed 
with a hemostat, and the catheter was attached to the con-
nector allowing successful placement. A second kit was not 
required in either case.
The 30-day T-SPeC® were our primary endpoints. The 
T-SPeC® device was successfully placed and provided 
bladder drainage for the desired duration in 98.2 % of 
patients. There were two premature catheter expulsions, 
and these were considered failures (1.8 %). In both men, 
the incident was due to patient factors, mental illness in one 
patient that lead to him pulling the catheter out with the 
balloon inflated and one patient who had the catheter pulled 
out while transferring from wheelchair to bed. Neither inci-
dent was due to catheter design or malfunction. The major-
ity of patients (89.5 %) did not have any complications in 
the 30 days following surgery. The most common postop-
erative complication was a urinary tract infection (UTI), 
occurring in six patients(5.3 %). Two of the six patients had 
a history of chronic UTIs. This number compares favorably 
with the 15.8 % incidence of preoperative recurrent UTIs in 
our study population. There were two minor wound infec-
tions successfully treated with antibiotics. In two patients, 
the SPC became permanently obstructed postoperatively 
with urinary sediment thereby requiring a urethral cath-
eter. In these two cases, the initial SPC was left in place 
for 30 days to establish the tract and then was successfully 
exchanged for a 20 Fr suprapubic catheter. Most impor-
tantly, there were no major complications (Clavien–Dindo 
Fig. 2  a–l Insertion of the sound per urethra and angling of the 
sound toward the abdominal wall (a). Attachment of the mast to the 
handle (b). Positioning of the alignment arm and blade capture hous-
ing (c). Unlocking the safety to allow advancement of the coaxial coil 
(d). Advancement of the blade attached to a coaxial coil from the tip 
of the sound through the abdominal wall (e). Removal of the capture 
housing which now contains the perforating blade that cuts through 
the abdominal wall (f–g). Attachment of the 18 Fr silicone catheter to 
the bayonet connector on the coaxial coil above the skin surface (h). 
Spreading of the 15 Fr tract to allow the 18 Fr catheter to pull into 
the bladder (i). Disconnection of the catheter by dividing the cathe-
ter where it was affixed to the bayonet connector (j). Advancing the 
catheter tip back into the bladder with a hemostat and inflation of the 
10-ml balloon with saline (k). Final position of the 18 Fr catheter (l)
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grade III–IV) such as bowel injury, vascular injury, death or 
need for re-operation.
Comments
Suprapubic cystostomy is commonly used for long-term 
as well as temporary urinary drainage. Patients requiring 
long-term urinary drainage would include those with a neu-
rogenic or end-stage bladder who are unable or unwilling 
to perform clean intermittent catheterization [3]. Patients 
needing long-term bladder drainage prefer chronic SPC to 
a Foley as it avoids the risk of urethral erosion [4]. Tempo-
rary SPC drainage is preferred by many surgeons for post-
operative urinary drainage due to improved patient com-
fort and ease of performing a voiding trial. For instance, 
Krane et al. [5] compared suprapubic bladder drainage to 
Foley drainage in 200 men undergoing robotic-assisted 
laparoscopic radical prostatectomy (RALP). They noted the 
patients who had a SPC had significantly decreased cath-
eter-related discomfort and a straightforward voiding trial 
allowing early catheter removal.
Although urologists recognize the short- and long-
term value of SPC, it remains an underutilized proce-
dure due to fear of life-threatening complications such as 
a bowel injury as well as a lack of a universal method for 
safe, efficient and accurate placement especially in obese 
patients [6–9]. Ahluwalia et al. [4] found a 10 % intra-oper-
ative complication rate, 2.5 % risk of bowel injury, 19 % 
30-day complications rate and a 1.8 % mortality rate in 219 
patients who underwent percutaneous suprapubic insertion 
under cystoscopic guidance. Similarly, the US Department 
of Health and Human Services, Agency for Healthcare 
Research and Quality (AHRQ) reported a ten-year average 
US mortality rate for SPC placement via the ‘outside-in’ 
methods of 4.4 %. More recently, the British Association 
Fig. 3  a Photograph of a 
morbidly obese woman (BMI 
of 47 kg/m2) with a neurogenic 
bladder secondary to multiple 
sclerosis (a). She is in the 
lithotomy position for suprapu-
bic catheter placement utilizing 
the T-SPeC® device under local 
anesthesia. The indications for 
the procedure were urinary 
retention and her inability to 
perform self-catheterization. 
The T-SPeC® T14 model is 
recommended in patients with 
BMI > 35 kg/m2. b T-SPeC® 
device measuring distance from 
edge of skin to bladder at 8 cm, 
implying an 8-cm-thick pannus. 
c Photograph of a morbidly 
obese woman (BMI of 50.2 kg/
m2) with a neurogenic bladder 
secondary to CVA. The indica-
tions for the procedure were uri-
nary retention and incontinence. 
Other comorbid conditions 
included a history of ileostomy 
and subsequent takedown. d 
T-SPeC® T14 device measur-
ing 8 cm from bladder to skin 
which exceeds the length of 
most percutaneous SPC trocars
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of Urologic Surgeons (BAUS) guidelines now recommend 
fluoroscopy or ultrasonography when using a percutaneous 
method [4]. Additionally, percutaneous suprapubic cath-
eters are often limited by a smaller caliber (8–14 Fr) that is 
prone to occlusion. This is especially true in patients with 
8–12 Fr biliary pigtail percutaneous catheter inserted by 
Interventional Radiology. Surprisingly, the use of a biliary 
catheter in the urinary tract has never been studied or FDA 
approved. The open abdominal approach under general 
anesthesia is still preferred by some urologists as it allows 
placement of a large caliber (20–24 Fr) catheter and avoids 
bowel injury [10]. The disadvantages to open abdominal 
approach are the need for abdominal dissection, length of 
the procedure, postoperative pain and convalescence that 
may necessitate hospital admission, placing a health and 
financial burden on the patient and healthcare system. 
Hence, there is a need for a medical device that allows a 
safe, efficient, and accurate method of suprapubic catheter 
placement particularly in the obese patient that comprised 
45.6 % of the population in our study and 35 % of the US 
population [11].
Prior abdominal surgery without simultaneous imaging 
(ultrasound, fluoroscopy, CT scan or even laparoscopy) 
is considered by some to be a contraindication to percu-
taneous SPC placement due to surgical adhesions that 
can lead to bowel injury. In our study, the T-SPeC® was 
placed safely without any intra-operative imaging. Preop-
erative imaging was needed in less than 10 % of patients. 
We did not experience a single bowel injury despite treat-
ing a population with previous gastrointestinal surgery 
(41.2 %), urological surgery (53.5 %) and gynecological 
surgery (71.9 %). Previous abdominal surgery did not put 
the patient at risk of bowel injury in our study as evident 
by the absence of bowel perforation in this study. How-
ever, we were selective in whom we would offer SPC 
placement using the T-SPeC® device and triaged 12 high-
risk patients during our study period to an open abdomi-
nal SPC placement. We believe the unique design of the 
T-SPeC® device allows safe suprapubic catheter placement 
in many patients with abdominal adhesions, but this cur-
rently is listed by the manufacturer as a contraindication 
for T-SPeC® insertion.
We found the T-SPeC® Surgical System to be safe 
and effective even in morbidly obese patients. Although 
the percutaneous trocar in the ‘outside-in’ kit may not 
always reach the bladder in the obese population, we have 
not found a single patient that exceeded the limits of the 
T14 device despite patients with BMI as great as 50 kg/
m2 [12]. Our T-SPeC® intra-operative (1.8 %) and 30-day 
postoperative (10.5 %) complication rate compares favora-
bly with the percutaneous SPC complication rate noted 
in the Ahluwalia study, 10 and 19 %, respectively [4]. 
Moreover, unlike Ahluwalia et al. [4], we did not have any 
bowel injuries or deaths. While not only safe, the T-SPeC® 
procedure takes average of only 3.6 min which compares 
favorably to an open abdominal approach. The primary 
disadvantage of the T-SPeC® device is that a patent ure-
thra is required. Therefore, five patients were triaged to a 
percutaneous approach during the study period. Also the 
patient needs to be positioned in the lithotomy position 
that can be challenging in patients with lower extremity 
contractures.
The primary study limitation was that 88 % of patients 
had concomitant pelvic surgery. We believe the feasibility; 
benefits and postoperative complications would have been 
better demonstrated if the procedure was done in isolation. 
Other study limitations include a single surgeon, single 
institution experience and the lack of a control group. Con-
sequently, we propose a multicenter study to demonstrate 
the outcome in isolated procedures. If these results prove 
encouraging, then a head-to-head, randomized, multicenter 
trial comparing operative time, success, safety, reliability 
and cost of T-SPeC® versus percutaneous SPC would be 
valuable.
Table 1  Patient demographics
Total number of patients 114
Mean age [years (range)] 57 (33–90)
BMI [kg/m2 (range)] 29 (17–50)
Sex
 Male [N (%)] 15 (13.2)
 Female [N (%)] 99 (86.8)
Indications
 Neurogenic bladder [N (%)] 14 (12.3)
  Incontinence 4
  Retention 10
 Female reconstructive surgery [N (%)] 89 (78.1)
  SUI 64
  LUT mesh perforation 13
  Fistula repair 9
  Urethral diverticulum repair 1
  Female urethroplasty 2
 Male reconstructive surgery [N (%)] 11 (9.6)
  Bladder diverticulum repair 1
  Urethral stricture or fistula repair 10
Comorbid conditions
 Obesity (BMI > 30 kg/m2) [N (%)] 52 (45.6)
 Prior radiation [N (%)] 3 (2.6)
 Neurologic conditions [N (%)] 14 (12.3)
 Chronic UTIs [N (%)] 18 (15.8)
Previous abdominal surgery 181
 Gastrointestinal [N (%)] 47 (41.2)
 Urological [N (%)] 61 (53.5)
 Gynecological [N (%)] 82 (71.9)
262 Int Urol Nephrol (2015) 47:257–262
1 3
Conclusion
The T-SPeC® device is a disposable medical device that 
allows a novel, simple and accurate method of placing a 
SPC from an ‘inside-to-out’ approach in a heterogeneous 
group of patients. Our US series of 114 patients is the larg-
est series to date and demonstrates that the T-SPeC® device 
could be placed safely and efficiently in a large group of 
patients requiring a suprapubic catheter. We believe that 
future studies will further demonstrate that the T-SPeC® 
has inherent advantages over current methods of SPC 
placement.
Conflict of interest Brian J. Flynn: Principal Investigator for Swan 
Valley Medical Incorporated. The first fifty T-SPeC® devices were 
provided by Swan Valley Medical. Robert J. Larke: None. Paul B. 
Knoll: None. Vassilis J. Siomos: None. Andrew P. Windsperger: 
None. Kirk M. Anderson: None.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution License which permits any use, distribu-
tion, and reproduction in any medium, provided the original author(s) 
and the source are credited.  
References
 1. Zeidman EJ, Chiang H, Alarcon A, Raz S (1988) Suprapubic cys-
tostomy using Lowsley retractor. Urology 32(1):54–55
 2. Karsh LI, Egerdie RB, Albala DM, Flynn BJ (2013) The transure-
thral suprapubic endo-cystostomy (T-SPeC): a novel suprapu-
bic catheter insertion device. J Endourol Soc 27(7):880–885. 
doi:10.1089/end.2013.0053
 3. Edokpolo LU, Foster HE Jr (2011) Suprapubic cystostomy for 
neurogenic bladder using Lowsley retractor method: a pro-
cedure revisited. Urology 78(5):1196–1198. doi:10.1016/j.
urology.2011.07.1393
 4. Ahluwalia RS, Johal N, Kouriefs C, Kooiman G, Montgom-
ery BS, Plail RO (2006) The surgical risk of suprapubic cath-
eter insertion and long-term sequelae. Ann R Coll Surg Engl 
88(2):210–213. doi:10.1308/003588406X95101
 5. Krane LS, Bhandari M, Peabody JO, Menon M (2009) Impact 
of percutaneous suprapubic tube drainage on patient discom-
fort after radical prostatectomy. Eur Urol 56(2):325–330. 
doi:10.1016/j.eururo.2009.04.018
 6. Ahmed SJ, Mehta A, Rimington P (2004) Delayed bowel perfora-
tion following suprapubic catheter insertion. BMC Urol 4(1):16. 
doi:10.1186/1471-2490-4-16
 7. Ananthakrishnan K, Ayyathurai R, Chiran JK, Islam W, Srini-
vasan V (2006) An unusual complication of suprapubic cath-
eter insertion. ScientificWorldJournal 6:2433–2435. doi:10.1100
/tsw.2006.378
 8. Barai KP, Islam S (2009) Suprapubic catheterization complicated 
by an iatrogenic enterocutaneous fistula: a case report. Cases J 
2:9311. doi:10.1186/1757-1626-2-9311
 9. Mongiu AK, Helfand BT, Kielb SJ (2009) Small bowel per-
foration during suprapubic tube exchange. Can J Urol 
16(1):4519–4521
 10. Feifer A, Corcos J (2008) Contemporary role of suprapubic cys-
tostomy in treatment of neuropathic bladder dysfunction in spi-
nal cord injured patients. Neurourol Urodyn 27(6):475–479. 
doi:10.1002/nau.20569
 11. Ogden CL, Carroll MD, Kit BK, Flegal KM (2014) Prevalence 
of childhood and adult obesity in the United States, 2011–2012. 
JAMA 311(8):806–814. doi:10.1001/jama.2014.732
 12. Irby PB 3rd, Stoller ML (1993) Percutaneous suprapubic cystos-
tomy. J Endourol 7(2):125–130
